Related Experiment Video

Updated: Mar 17, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Targeted PET imaging for prostate-specific membrane antigen in prostate cancer

Thomas A Hope1,2, Rahul R Aggarwal3, Antonio C Westphalen1

  • 1Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA.

Future Oncology (London, England)
|July 26, 2016
PubMed
Abstract

No abstract available in PubMed .

Keywords:
PETPSMAprostate cancerprostate-specific membrane antigen

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.9K

Related Experiment Videos

Last Updated: Mar 17, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
12:24

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers

Published on: July 17, 2012

12.9K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

8.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.0K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

713
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
713

Articles linked to this work by shared authors, journal, and citation graph.

Standardizing serial prostate MRI in active surveillance: a practical review of PRECISE scoring.

Abdominal radiology (New York)·2026

Medical Appointments are Associated With Same-Day Worry and Sleep Difficulties Among Cancer Survivors.

Psycho-oncology·2026

The clinical utility of prostate MRI before biopsy.

Nature reviews. Urology·2026

Artificial Intelligence Sees the Image, Radiologists See the Patient.

AJR. American journal of roentgenology·2026

PRECISE Version 2: Essential Tips for Prostate Cancer Monitoring Using MRI.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026

MRI for Prostate Cancer Local Staging: AJR Expert Panel Narrative Review.

AJR. American journal of roentgenology·2025

PSMA-PET/mpMRI-guided focal dose-escalated stereotactic body radiotherapy for localized prostate cancer: study protocol for a prospective, randomized controlled trial.

Future oncology (London, England)·2026

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors.

Future oncology (London, England)·2026

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences.

Future oncology (London, England)·2026

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing.

Future oncology (London, England)·2026

Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.

Future oncology (London, England)·2026

TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10.

Future oncology (London, England)·2026

Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026

Bracing versus balloon kyphoplasty for acute osteoporotic vertebral fractures with poor prognostic radiological factors: a propensity score-matched comparison.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026

Complete bilateral spontaneous pneumothorax at moderate altitude revealing Marfan syndrome: a case report.

AME case reports·2026

External Validation of the PROMOD Strategy, Combining PI-RADS Score and PSA Density, to Select Patients for Prostatic Biopsies.

Research and reports in urology·2026

Zone-Specific PSA Density from AI-Assisted mp-MRI as a Predictor of Prostate Cancer in the PSA 4-20 ng/mL Range.

Journal of clinical medicine·2026

Patella Alta on X-Ray and MRI: Diagnostic Agreement and Clinical Correlations.

Diagnostics (Basel, Switzerland)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us